Search

Your search keyword '"Salvi, Flavia"' showing total 194 results
Start Over Author "Salvi, Flavia" Language english
194 results on '"Salvi, Flavia"'

1. Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study

Author

Rigacci, Luigi, Puccini, Benedetta, Broccoli, Alessandro, Dona, Manjola, Gotti, Manuel, Evangelista, Andrea, Santoro, Armando, Bonfichi, Maurizio, Re, Alessandro, Spina, Michele, Botto, Barbara, Pulsoni, Alessandro, Pagani, Chiara, Stelitano, Caterina, Salvi, Flavia, Nassi, Luca, Mannelli, Lara, Kovalchuk, Sofia, Gioia, Daniela, and Zinzani, Pier Luigi

Published
2020
Full Text
View/download PDF

2. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Author

Oliva, Esther N, Alati, Caterina, Santini, Valeria, Poloni, Antonella, Molteni, Alfredo, Niscola, Pasquale, Salvi, Flavia, Sanpaolo, Grazia, Balleari, Enrico, Germing, Ulrich, Fenaux, Pierre, Stamatoullas, Aspasia, Palumbo, Giuseppe A, Salutari, Prassede, Impera, Stefana, Avanzini, Paolo, Cortelezzi, Agostino, Liberati, Anna Marina, Carluccio, Paola, Buccisano, Francesco, Voso, Maria Teresa, Mancini, Stefano, Kulasekararaj, Austin, Morabito, Fortunato, Bocchia, Monica, Cufari, Patrizia, Spiriti, Maria Antonietta Aloe, Santacaterina, Irene, D'Errigo, Maria Grazia, Bova, Irene, Zini, Gina, and Latagliata, Roberto

Published
2017
Full Text
View/download PDF

3. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

Author

Visco, Carlo, Chiappella, Annalisa, Nassi, Luca, Patti, Caterina, Ferrero, Simone, Barbero, Daniela, Evangelista, Andrea, Spina, Michele, Molinari, Annalia, Rigacci, Luigi, Tani, Monica, Rocco, Alice Di, Pinotti, Graziella, Fabbri, Alberto, Zambello, Renato, Finotto, Silvia, Gotti, Manuel, Carella, Angelo M, Salvi, Flavia, Pileri, Stefano A, Ladetto, Marco, Ciccone, Giovannino, Gaidano, Gianluca, Ruggeri, Marco, Martelli, Maurizio, and Vitolo, Umberto

Published
2017
Full Text
View/download PDF

4. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

Author

Vitolo, Umberto, Chiappella, Annalisa, Franceschetti, Silvia, Carella, Angelo Michele, Baldi, Ileana, Inghirami, Giorgio, Spina, Michele, Pavone, Vincenzo, Ladetto, Marco, Liberati, Anna Marina, Molinari, Anna Lia, Zinzani, Pierluigi, Salvi, Flavia, Fattori, Pier Paolo, Zaccaria, Alfonso, Dreyling, Martin, Botto, Barbara, Castellino, Alessia, Congiu, Angela, Gaudiano, Marcello, Zanni, Manuela, Ciccone, Giovannino, Gaidano, Gianluca, and Rossi, Giuseppe

Published
2014
Full Text
View/download PDF

5. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems

Author

Buckstein, Rena, Balleari, Enrico, Wells, Richard, Santini, Valeria, Sanna, Alessandro, Salvetti, Chiara, Crisà, Elena, Allione, Bernardino, Danise, Paolo, Finelli, Carlo, Clavio, Marino, Poloni, Antonella, Salvi, Flavia, Cilloni, Daniela, Oliva, Esther Natalie, Musto, Pellegrino, Houston, Brett, Zhu, Nancy, Geddes, Michelle, Leitch, Heather, Leber, Brian, Sabloff, Mitchell, Nevill, Thomas J., Yee, Karen W., Storring, John M., Francis, Janika, Maurillo, Luca, Latagliata, Roberto, Spiriti, Maria Antonietta Aloe, Andriani, Alessandro, Piccioni, Anna Lina, Fianchi, Luana, Fenu, Susanna, Gumenyuk, Svitlana, and Buccisano, Francesco

Published
2017
Full Text
View/download PDF

6. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP

Author

Pregno, Patrizia, Chiappella, Annalisa, Bellò, Marilena, Botto, Barbara, Ferrero, Simone, Franceschetti, Silvia, Giunta, Francesca, Ladetto, Marco, Limerutti, Giorgio, Menga, Massimo, Nicolosi, Maura, Priolo, Giorgio, Puccini, Benedetta, Rigacci, Luigi, Salvi, Flavia, Vaggelli, Luca, Passera, Roberto, Bisi, Gianni, and Vitolo, Umberto

Published
2012
Full Text
View/download PDF

7. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

Author

Efficace, Fabio, Santini, Valeria, La Nasa, Giorgio, Cottone, Francesco, Finelli, Carlo, Borin, Lorenza, Quaresmini, Giulia, Di Tucci, Anna Angela, Volpe, Antonio, Cilloni, Daniela, Quarta, Giovanni, Sanpaolo, Grazia, Rivellini, Flavia, Salvi, Flavia, Molteni, Alfredo, Voso, Maria Teresa, Alimena, Giuliana, Fenu, Susanna, Mandelli, Franco, and Angelucci, Emanuele

Published
2016
Full Text
View/download PDF

8. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)

Author

Zallio, Francesco, Tamiazzo, Stefania, Monagheddu, Chiara, Merli, Francesco, Ilariucci, Fiorella, Stelitano, Caterina, Liberati, Anna Marina, Mannina, Donato, Vitolo, Umberto, Angelucci, Emanuele, Scalabrini, Delia Rota, Vallisa, Daniele, Bellei, Monica, Bari, Alessia, Ciccone, Giovannino, Salvi, Flavia, and Levis, Alessandro

Published
2016
Full Text
View/download PDF

13. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)

Author

Angelucci, Emanuele, Santini, Valeria, Di Tucci, Anna Angela, Quaresmini, Giulia, Finelli, Carlo, Volpe, Antonio, Quarta, Giovanni, Rivellini, Flavia, Sanpaolo, Grazia, Cilloni, Daniela, Salvi, Flavia, Caocci, Giovanni, Molteni, Alfredo, Vallisa, Daniele, Voso, Maria Teresa, Fenu, Susanna, Borin, Lorenza, Latte, Giancarlo, Alimena, Giuliana, Storti, Sergio, Piciocchi, Alfonso, Fazi, Paola, Vignetti, Marco, and Tura, Sante

Published
2014
Full Text
View/download PDF

14. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi

Author

Merli, Francesco, Cavallo, Federica, Salvi, Flavia, Tucci, Alessandra, Musuraca, Gerardo, Nassi, Luca, Merli, Michele, Tani, Monica, Gini, Guido, Ferrari, Angela, Molinari, Anna Lia, Liberati, Anna Marina, Conconi, Annarita, Matteucci, Paola, Bari, Alessia, Scalone, Renato, Ferrero, Simone, Zanni, Manuela, Mammi, Caterina, and Luminari, Stefano

Published
2020
Full Text
View/download PDF

15. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi

Author

Rigacci, Luigi, Vitolo, Umberto, Nassi, Luca, Merli, Francesco, Gallamini, Andrea, Pregno, Patrizia, Alvarez, Isabel, Salvi, Flavia, Sancetta, Rosaria, Castagnoli, Antonio, Versari, Annibale, Biggi, Alberto, Gregianin, Michele, Pelosi, Ettore, Chisesi, Teodoro, Bosi, Alberto, Levis, Alessandro, and On behalf of Intergruppo Italiano Linfomi

Published
2007
Full Text
View/download PDF

17. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes

Author

Falco, Patrizia, Levis, Alessandro, Stacchini, Alessandra, Ciriello, Maria M., Geuna, Massimo, Notari, Patrizia, Omedè, Paola, Pautasso, Marisa, Prato, Giuseppina, Strola, Giuliana, Gioia, Daniela, Bonferroni, Margherita, Cametti, Gianni, Ferrero, Dario, Freilone, Roberto, Gaidano, Gianluca, Marinone, Carlo, Marmont, Filippo, Pollio, Berardino, Salvi, Flavia, Saglio, Giuseppe, and Girotto, Mauro

Published
2011
Full Text
View/download PDF

18. A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study)

Author

Cattaneo, Chiara, Monte, Simona, Algarotti, Alessandra, Audisio, Ernesta, Borlenghi, Erika, Campiotti, Leonardo, Cerqui, Elisa, Fanizza, Caterina, Giuliani, Rachele, Micò, Caterina, Rocconi, Roberta, Salvi, Anna, Salvi, Flavia, Verga, Luisa, Levis, Alessandro, Lambertenghi Deliliers, Giorgio, Pogliani, Enrico M., Tognoni, Gianni, Rambaldi, Alessandro, and Rossi, Giuseppe

Published
2011
Full Text
View/download PDF

19. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors

Author

Latagliata, Roberto, Breccia, Massimo, Fazi, Paola, Vignetti, Marco, Di Raimondo, Francesco, Sborgia, Marco, Vincelli, Donatella, Candoni, Anna, Salvi, Flavia, Rupoli, Serena, Martinelli, Giovanni, Kropp, Maria Grazia, Tonso, Anna, Venditti, Adriano, Melillo, Lorella, Cimino, Giuseppe, Petti, Maria Concetta, Avvisati, Giuseppe, Lo-Coco, Francesco, and Mandelli, Franco

Published
2011
Full Text
View/download PDF

22. A Large-Scale Study of Bone Marrow Involvement in Patients with Hodgkinʼs Lymphoma

Author

Levis, Alessandro, Pietrasanta, Daniela, Godio, Laura, Vitolo, Umberto, Ciravegna, Giorgio, Vito, Francesco Di, Gavarotti, Paolo, Guglielmelli, Tommasina, Orsucci, Lorella, Raviolo, Ermanno, Scalabrini, Delia Rota, Salvi, Flavia, Tonso, Anna, Aglietta, Massimo, Boccadoro, Mario, Gallamini, Andrea, Saglio, Giuseppe, Scassa, Enzo, and Gallo, Eugenio

Published
2004

24. Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study

Author

Galimberti Sara, Guerrini Francesca, Salvi Flavia, Petrini Iacopo, Gioia Daniela, Messa Emanuela, Palumbo Giuseppe A, Cilloni Daniela, Petrini Mario, and Levis Alessandro

Subjects
ATO, Ascorbic acid, Myelodysplastic syndromes, MDS, Apoptosis, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Arsenic Trioxide (ATO) is effective in about 20% of patients with myelodysplasia (MDS); its mechanisms of action have already been evaluated in vitro, but the in vivo activity is still not fully understood. Since ATO induces apoptosis in in vitro models, we compared the expression of 93 apoptotic genes in patients’ bone marrow before and after ATO treatment. For this analysis, we selected 12 patients affected by MDS who received ATO in combination with Ascorbic Acid in the context of the Italian clinical trial NCT00803530, EudracT Number 2005-001321-28. Methods Real-time PCR quantitative assays for genes involved in apoptosis were performed using TaqMan® Assays in 384-Well Microfluidic Cards “TaqMan® Human Apoptosis Array”. Quantitative RT-PCR for expression of EVI1 and WT1 genes was also performed. Gene expression values (Ct) were normalized to the median expression of 3 housekeeping genes present in the card (18S, ACTB and GAPDH). Results ATO treatment induced up-regulation of some pro-apoptotic genes, such as HRK, BAK1, CASPASE-5, BAD, TNFRSF1A, and BCL2L14 and down-regulation of ICEBERG. In the majority of cases with stable disease, apoptotic gene expression profile did not change, whereas in cases with advanced MDS more frequently pro-apoptotic genes were up-regulated. Two patients achieved a major response: in the patient with refractory anemia the treatment down-regulated 69% of the pro-apoptotic genes, whereas 91% of the pro-apoptotic genes were up-regulated in the patient affected by refractory anemia with excess of blasts-1. Responsive patients showed a higher induction of BAD than those with stable disease. Finally, WT1 gene expression was down-regulated by the treatment in responsive cases. Conclusions These results represent the basis for a possible association of ATO with other biological compounds able to modify the apoptotic pathways, such as inhibitors of the BCL2 family.

Published
2012
Full Text
View/download PDF

25. Rituximab plus bendamustine as front-line treatment in frail elderly ( extgreater70 years) patients with diffuse large b-cell non-hodgkin lymphoma: A phase ii multicenter study of the fondazione italiana linfomi

Author

Storti, Sergio, Spina, Michele, Pesce, Emanuela, Anna, Salvi, Flavia, Merli, Michele, Ruffini, Alessia, Cabras, Giuseppina, Chiappella, Annalisa, Angelucci, Emanuele, Fabbri, Alberto, Liberati Anna Marina, Tanim, Onica, Musuraca, Gerardo, Molinari, Annalia, Petrilli Maria Pia, Palladino, Carmela, Ciancia, Rosanna, Ferrario, Andrea, Gasbarrino, Cristiana, Monaco, Federico, Fraticelli, Vincenzo, De Vellis Annalisa, Merli, Francesco, and Luminari, Stefano

Subjects
0301 basic medicine, Bendamustine, Male, medicine.medical_specialty, Neutropenia, Lymphoma, Frail Elderly, Phases of clinical research, Infections, 03 medical and health sciences, 0302 clinical medicine, Median follow-up, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, 80 and over, Large B-Cell, Bendamustine Hydrochloride, Humans, Adverse effect, Survival analysis, Aged, Aged, 80 and over, business.industry, Remission Induction, Hematology, medicine.disease, Survival Analysis, Diffuse, Clinical trial, Consolidation Chemotherapy, Settore MED/15 - MALATTIE DEL SANGUE, 030104 developmental biology, Treatment Outcome, Italy, 030220 oncology & carcinogenesis, Rituximab, Female, Lymphoma, Large B-Cell, Diffuse, business, medicine.drug
Abstract

We conducted a phase II study to assess activity and safety profile of bendamustine and rituximab in elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) who were prospectively defined as frail using a simplified version of the Comprehensive Geriatric Assessment (CGA). Patients had to be over 70 years of age, with histologically confirmed DLBCL. Frail patients were those younger than 80 years with a frail profile at CGA or older than 80 years with an unfit profile. Treatment consisted of 4-6 courses of bendamustine [90 mg/m2 days (d)1-2] and rituximab (375 mg/m2 d1) administered every 28 days. Other main study end points were complete remission rate and the rate of extra-hematologic adverse events. Forty-nine patients were enrolled of whom 45 were confirmed eligible. Overall, 24 patients achieved a complete remission (53%; 95%CI: 38-68%) and the overall response rate was 62% (95%CI: 47-76%). The most frequent grade 3-4 adverse event was neutropenia (37.8%). Grade 3-4 extra-hematologic adverse events were observed in 7 patients (15.6%; 95%CI: 6.5-29.5%); the most frequent was grade 3 infection in 2 patients. With a median follow up of 33 months (range 1-52), the median progression-free survival was ten months (95%CI: 7-25). The study shows promising activity and manageable toxicity profile of BR combination as first-line therapy for patients with DLBCL who are prospectively defined as frail according to a simplified CGA, as adopted in this trial (clinicaltrials.gov identifier: 01990144).

Published
2018

26. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Author

Ladetto, Marco, Corradini, Paolo, Vallet, Sonia, Benedetti, Fabio, Vitolo, Umberto, Martelli, Maurizio, Brugiatelli, Maura, Coser, Paolo, Perrotti, Alessio, Majolino, Ignazio, Fioritoni, Giuseppe, Morandi, Sergio, Musso, Maurizio, Zambello, Renato, Chisesi, Teodoro, Di Renzo, Nicola, Vivaldi, Paolo, De Crescenzo, Alberto, Gallamini, Andrea, Salvi, Flavia, Santini, Gino, Boccomini, Carola, Sorio, Marco, Astolfi, Monica, Drandi, Daniela, Pileri, Alessandro, and Tarella, Corrado

Published
2002
Full Text
View/download PDF

27. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.

Author

Clavio, Marino, Crisà, Elena, Miglino, Maurizio, Guolo, Fabio, Ceccarelli, Manuela, Salvi, Flavia, Allione, Bernardino, Ferrero, Dario, Balleari, Enrico, Finelli, Carlo, Poloni, Antonella, Selleri, Carmine, Danise, Paolo, Cilloni, Daniela, Di Tucci, Anna Angela, Cametti, Gianni, Freilone, Roberto, Fanin, Renato, Bigazzi, Catia, and Zambello, Renato

Subjects
OVERALL survival, MYELODYSPLASTIC syndromes, HEMATOPOIETIC stem cell transplantation, AZACITIDINE, TERMINATION of treatment
Abstract

Background: Azacitidine (AZA) is the standard treatment for myelodysplastic syndromes (MDS); however, many patients prematurely stop therapy and have a dismal outcome.Methods: The authors analyzed outcomes after AZA treatment for 402 MDS patients consecutively enrolled in the Italian MDS Registry of the Fondazione Italiana Sindromi Mielodisplastiche, and they evaluated the North American MDS Consortium scoring system in a clinical practice setting.Results: At treatment discontinuation, 20.3% of the patients were still responding to AZA, 35.4% of the cases had primary resistance, and 44.3% developed adaptive resistance. Overall survival (OS) was better for patients who discontinued treatment while in response because of planned allogeneic hematopoietic stem cell transplantation (HSCT; median OS, not reached) in comparison with patients with primary resistance (median OS, 4 months) or adaptive resistance (median OS, 5 months) or patients responsive but noncompliant/intolerant to AZA (median OS, 4 months; P = .004). After AZA discontinuation, 309 patients (77%) received best supportive care (BSC), 60 (15%) received active treatments, and 33 (8%) received HSCT. HSCT was associated with a significant survival advantage, regardless of the response to AZA. The North American MDS Consortium scoring system was evaluable in 278 of the 402 cases: patients at high risk had worse OS than patients at low risk (3 and 7 months, respectively; P < .001). The score was predictive of survival both in patients receiving BSC (median OS, 2 months for high-risk patients vs 5 months for low-risk patients) and in patients being actively treated (median OS, 8 months for high-risk patients vs 16 months for low-risk patients; P < .001), including transplant patients.Conclusions: Real-life data confirm that this prognostic scoring system for MDS patients failing a hypomethylating agent seems to be a useful tool for optimal prognostic stratification and for choosing a second-line treatment after AZA discontinuation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis

Author

Beyne-Rauzy, Odile, Sebert, Marie, Sapena, Rosa, Zerazhi, Hacène, Legros, Laurence, Guerci-Bresler, Agnès, Ame, Shanti Natarjan, Germing, Ulrich, Santini, Valeria, Salvi, Flavia, Gioia, Daniela, Lunghi, Monia, Dreyfus, François, Fenaux, Pierre, Sindromi, Fdn Italiana, Registry, Dusseldorf Mds, Gyan, Emmanuel, Andrieu, Valerie, Sanna, Alessandro, Caille, Agnès, Schemenau, Jennifer, Sudaka, Isabelle, Siguret, Virginie, Malet, Michele, Park, Sophie, Bordessoule, Dominique, Mairesse, Jacques, Gelsi-Boyer, Véronique, Cheze, Stephane, Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Médecine Interne Onco-hématologie, Centre Hospitalier Général, Service d'Hématologie Clinique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Department of Haematology, Oncology and Clinical Immunology, Centre for Haematology and Oncology, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Service d'hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hémopathies Myéloïdes : Cellules Souches, Modèles Pré-Cliniques et Recherche Translationnelle (UMR 1131), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d’Hématologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CIC - Tours, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Thrombose : Épidémiologie, Physiopathologie et Thérapeutiques Innovantes (UMR_S 765), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Économie et Statistique (CREST), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] (ENSAI)-École polytechnique (X)-École Nationale de la Statistique et de l'Administration Économique (ENSAE Paris)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne et Immunopathologie, CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Heinrich-Heine-Universität Düsseldorf [Düsseldorf], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Hémopathies Myéloïdes : Cellules Souches, Modèles Pré-Cliniques et Recherche Translationnelle, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], IUH- Institut Universitaire d'hématologie, Université Paris Diderot - Paris 7 ( UPD7 ), CHRU Tours, CHRU Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), CIC 1415, Institut National de la Santé et de la Recherche Médicale-Université Francois Rabelais [Tours], Thrombose : Épidémiologie, Physiopathologie et Thérapeutiques Innovantes ( UMR_S 765 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Cochin [AP-HP], Contrôle de la Réponse Immune B et des Lymphoproliférations ( CRIBL ), Université de Limoges ( UNILIM ) -Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche en Économie et Statistique ( CREST ), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] ( ENSAI ) -École polytechnique ( X ) -École Nationale de la Statistique et de l'Administration Économique ( ENSAE ParisTech ), Centre de Recherche en Cancérologie de Marseille ( CRCM ), Aix Marseille Université ( AMU ) -Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Francois Rabelais [Tours], Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] (ENSAI)-École polytechnique (X)-École Nationale de la Statistique et de l'Administration Économique (ENSAE ParisTech )-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Pediatrics, medicine.medical_specialty, classifications, diagnostic haematology, MDS, neutropenia, thrombocytopenia, Hematology, business.industry, Myelodysplastic syndromes, Neutropenia, medicine.disease, World health, 3. Good health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 03 medical and health sciences, 0302 clinical medicine, Refractory, Dysplasia, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030220 oncology & carcinogenesis, Immunology, medicine, Young adult, business, ComputingMilieux_MISCELLANEOUS, 030215 immunology
Abstract

International audience; no abstract

Published
2016
Full Text
View/download PDF

30. Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).

Author

Salvi, Flavia, Luminari, Stefano, Tucci, Alessandra, Massidda, Stefania, Liberati, Anna Marina, Stelitano, Caterina, Zanni, Manuela, Re, Alessandro, Centurioni, Riccardo, Freilone, Roberto, Musuraca, Gerardo, Nassi, Luca, Patti, Caterina, Arcari, Annalisa, Tani, Monica, Pulsoni, Alessandro, Pavone, Vincenzo, Volpetti, Stefano, Peli, Annalisa, and Evangelista, Andrea

Subjects
*HODGKIN'S disease, *BLEOMYCIN, *DOXORUBICIN, *DACARBAZINE, *PROGRESSION-free survival
Abstract

This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I–IIA and IIB–IV patients were treated with three courses of MBVD plus radiotherapy, or six courses of MBVD, respectively, plus radiotherapy limited to bulky or residual disease areas. The primary endpoints were CR rate and the rate of cardiac events. Forty-seven patients were enrolled. Median age was 75 years, 13 had stage I–II disease. Overall, CR was achieved by 36 patients (77%, 95% CI: 62–88), 100% and 68% in stage I–II and III–IV, respectively. With a median follow-up of 40 months (IQR: 36–45). Three-year overall survival (OS) and progression-free survival (PFS) were 70% and 43%, respectively. Cardiac events grades 3–5 were reported in two patients. In conclusion, MBVD's activity and safety profile was comparable to historical ABVD data. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

31. Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Author

Fabiani, Emiliano, Calabrese, Chiara, Niscola, Pasquale, Balleari, Enrico, Molteni, Alfredo, Finelli, Carlo, Falconi, Giulia, Fenu, Susanna, Fianchi, Luana, Criscuolo, Marianna, Salvi, Flavia, Lavorgna, Serena, Buccisano, Francesco, Maurillo, Luca, Lo Coco, Francesco, Cilloni, Daniela, and Voso, Maria Teresa

Subjects
MYELOFIBROSIS, MYELODYSPLASTIC syndromes, CHELATION
Abstract

The article focuses on a study which analyzes somatic mutations and haematological response to iron chelation in myelodysplastic syndromes (MDS). Topics being presented include the molecular mechanisms associated with haematological improvement during iron chelating treatment in MDS and the use of oral iron chelator deferasirox according to guidelines in patients with MDS or primary myelofibrosis.

Published
2019
Full Text
View/download PDF

33. Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.

Author

Zaja, Francesco, Salvi, Flavia, Rossi, Maura, Sabattini, Elena, Evangelista, Andrea, Ciccone, Giovannino, Angelucci, Emanuele, Gaidano, Gianluca, Zanni, Manuela, Ladetto, Marco, Chiappella, Annalisa, Vitolo, Umberto, Zinzani, Pier Luigi, Califano, Catello, Tucci, Alessandra, Patti, Caterina, Pileri, Stefano A., Lenti, Valentina, Piccaluga, Pier Paolo, and Cavallo, Federica

Subjects
*B cell lymphoma, *THROMBOCYTOPENIA, *DISEASE relapse, *GENETIC mutation, *STATISTICAL correlation
Abstract

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

34. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.

Author

Luminari, Stefano, Ferrari, Angela, Manni, Martina, Dondi, Alessandra, Chiarenza, Annalisa, Merli, Francesco, Rusconi, Chiara, Tarantino, Vittoria, Tucci, Alessandra, Vitolo, Umberto, Kovalchuk, Sofia, Angelucci, Emanuele, Pulsoni, Alessandro, Arcaini, Luca, Angrilli, Francesco, Gaidano, Gianluca, Stelitano, Caterina, Bertoldero, Giovanni, Cascavilla, Nicola, and Salvi, Flavia

Published
2018
Full Text
View/download PDF

36. IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Author

Stathis, Anastasios, Gregorini, Anna, Gressin, Remy, Orsucci, Lorella, Perrot, Aurore, Tani, Monica, Coiffier, Bertrand, Musuraca, Gerardo, Guieze, Romain, Marino, Dario, Gini, Guido, Ferrari, Angela, Gyan, Emmanuel, Morschhauser, Franck, Palombi, Francesca, Cavallo, Federica, Le Gouill, Steven, Tilly, Herve, Salvi, Flavia, Conconi, Annarita, Cabras, Maria Giuseppina, Capochiani, Enrico, Califano, Catello, Molinari, Anna Lia, Pulsoni, Alessandro, Ielmini, Nicoletta, Luminari, Stefano, Cavalli, Franco, Zucca, Emanuele, and Thieblemont, Catherine

Published
2017
Full Text
View/download PDF

37. Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study.

Author

Zwarthoed, Colette, El-Galaly, Tarec Cristoffer, Canepari, Maria, Ouvrier, Matthieu John, Viotti, Julien, Ettaiche, Marc, Viviani, Simonetta, Rigacci, Luigi, Trentin, Livio, Rusconi, Chiara, Luminari, Stefano, Cantonetti, Maria, Bolis, Silvia, Borra, Anna, Darcourt, Jacques, Salvi, Flavia, Subocz, Edyta, Tajer, Joanna, Kulikowski, Waldemar, and Malkowski, Bogdan

Published
2017
Full Text
View/download PDF

38. Mother Donors Improve Outcomes after HLA Haploidentical Hematopoietic Transplantation: A Retrospective Study By the Cell Therapy and Immunobiology Working Party of the EBMT

Author

Velardi, Andrea, Ruggeri, Loredana, Ziagkos, Dimitris, van Biezen, Anja, Merluzzi, Mara, Bondanza, Attilio, Bootsman, Nathasja, Massei, Maria Speranza, Amico, Lucia, Piccinelli, Sara, Noviello, Maddalena, Ciceri, Fabio, Klingebiel, Thomas, Koc, Yener, Veelken, Hendrik, Locatelli, Franco, Arcese, William, Gruhn, Bernd, Salvi, Flavia, Bonini, Chiara, and van Rood, Jon J.

Published
2016
Full Text
View/download PDF

39. The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma

Author

Merli, Francesco, Luminari, Stefano, Tucci, Alessandra, Cavallo, Federica, Mammi, Caterina, Rigacci, Luigi, Finolezzi, Erica, Cabras, Giuseppina, Fabbri, Alberto, Zilioli, Vittorio Ruggero, Marino, Dario, Chiappella, Annalisa, Balzarotti, Monica, Arcari, Annalisa, Gini, Guido, Salvi, Flavia, Hohaus, Stefan, Tani, Monica, Sartori, Roberto, Cox, Maria Christina, Marcheselli, Luigi, and Spina, Michele

Published
2016
Full Text
View/download PDF

40. Feasibility of Allogeneic Stem Cell Transplantation After Azacitidine in Patients with High Risk Myelodysplastic Syndromes or Low-Blast Count Acute Myeloid Leukemias: the Experience of the BMT-AZA Multicenter Prospective Study

Author

Voso, Maria Teresa, Criscuolo, Marianna, Leone, Giuseppe, Piciocchi, Alfonso, Fianchi, Luana, Santarone, Stella, Candoni, Anna, Masciulli, Arianna, Cerqui, Elisa, Molteni, Alfredo, Finelli, Carlo, Parma, Matteo, Poloni, Antonella, Cascavilla, Nicola, Spina, Francesco, Cortelezzi, Agostino, Salvi, Flavia, Alessandrino, Emilio, Rambaldi, Alessandro, Bacigalupo, Andrea, and Sica, Simona

Published
2016
Full Text
View/download PDF

41. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).

Author

Balzarotti, Monica, Brusamolino, Ercole, Angelucci, Emanuele, Carella, Angelo Michele, Vitolo, Umberto, Russo, Eleonora, Congiu, Angelagiovanna, Gotti, Manuel, Massidda, Stefania, Botto, Barbara, Annechini, Giorgia, Spina, Michele, Re, Alessandro, Zilioli, Vittorio Ruggero, Merli, Francesco, Salvi, Flavia, Stelitano, Caterina, Bonfichi, Maurizio, Rodari, Marcello, and Murru, Roberta

Subjects
LYMPHOMA treatment, HODGKIN'S disease, CANCER chemotherapy, STEM cell transplantation, RANDOMIZED controlled trials
Abstract

This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m2) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%;p = 0.002) and OS (two-year OS: 100% vs 76%;p < 0.001). Toxicity was overall similar with the two regimens. The addition of bortezomib to IGEV does not improve response in relapsed/refractory HL patients. However, its favorable therapeutic and safety profile, and the prognostic role of pre-transplant PET negativity in patients receiving IGEV-based regimens are confirmed. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

42. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.

Author

Santoro, Armando, Mazza, Rita, Pulsoni, Alessandro, Re, Alessandro, Bonfichi, Maurizio, Zilioli, Vittorio Ruggero, Salvi, Flavia, Merli, Francesco, Anastasia, Antonella, Luminari, Stefano, Annechini, Giorgia, Gotti, Manuel, Peli, Annalisa, Liberati, Anna Marina, Di Renzo, Nicola, Castagna, Luca, Giordano, Laura, Carlo-Stelal, Carmelo, and Carlo-Stella, Carmelo

Published
2016
Full Text
View/download PDF

43. Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Author

Zinzani, Pier Luigi, Broccoli, Alessandro, Gioia, Daniela Maria, Castagnoli, Antonio, Ciccone, Giovannino, Evangelista, Andrea, Santoro, Armando, Ricardi, Umberto, Bonfichi, Maurizio, Brusamolino, Ercole, Rossi, Giuseppe, Anastasia, Antonella, Zaja, Francesco, Vitolo, Umberto, Pavone, Vincenzo, Pulsoni, Alessandro, Rigacci, Luigi, Gaidano, Gianluca, Stelitano, Caterina, and Salvi, Flavia

Published
2016
Full Text
View/download PDF

44. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.

Author

Pellegrini, Cinzia, Dodero, Anna, Chiappella, Annalisa, Monaco, Federico, Degl'Innocenti, Debora, Salvi, Flavia, Vitolo, Umberto, Argnani, Lisa, Corradini, Paolo, and Zinzani, Pier Luigi

Subjects
T-cell lymphoma, DISEASE relapse, RESPONSE rates, THROMBOCYTOPENIA, HEMATOLOGIC malignancies, PATIENTS
Abstract

Background: There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall survival of 30 %. Methods: A multicenter prospective phase II trial was conducted to investigate the role of the combination of gemcitabine plus romidepsin (GEMRO regimen) in relapsed/refractory PTCL, looking for a potential synergistic effect of the two drugs. GEMRO regimen contemplates an induction with romidepsin plus gemcitabine for six 28-day cycles followed by maintenance with romidepsin for patients in at least partial remission. The primary endpoint was the overall response rate (ORR); secondary endpoints were survival, duration of response, and safety of the regimen. Results: The ORR was 30 % (6/20) with 15 % (3) complete response (CR) rate. Two-year overall survival was 50 % and progression-free survival 11.2 %. Grade ⩾3 adverse events were represented by thrombocytopenia (60 %), neutropenia (50 %), and anemia (20 %). Two patients are still in CR with median response duration of 18 months. The majority of non-hematological toxicities were mild and transient. No treatment-related death occurred and no toxicity led to treatment interruption. Conclusions: GEMRO combination regimen shows efficacy data similar to those of single-agent romidepsin with additional hematologic toxicities. Synergy observed in preclinical phase did not turn into ability to improve clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

45. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

Author

Luminari, Stefano, Goldaniga, Maria, Cesaretti, Marina, Orsucci, Lorella, Tucci, Alessandra, Pulsoni, Alessandro, Salvi, Flavia, Arcaini, Luca, Carella, Angelo Michele, Tedeschi, Alessandra, Pinto, Antonello, Stelitano, Caterina, and Baldini, Luca

Subjects
RITUXIMAB, LYMPHOMA treatment, COMBINATION drug therapy, THROMBOCYTOPENIA treatment, PROGRESSION-free survival
Abstract

The purpose of this phase 2 study was to determine the activity and safety of six cycles of bendamustine and eight rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary end-point was the complete response rate (CRR) with expected CRR of 75%. Sixty-nine patients were enrolled; median age was 65 years (45–75), 65% were male, 93% of patients had stage IV disease. Complete and overall response rates were 48% (95% CI = 35.6–60.2) and 86% (CI = 75.0–92.8). The most common grade 3/4 adverse events were neutropenia (43%), thrombocytopenia (7%) and anemia (4%); whereas the rate of febrile neutropenia was very low (3%). At a median follow-up of 22 months (1–43 months), 2-year progression-free survival was 89% (CI = 79–95) and 2-year overall survival was 96% (CI = 87–99). RB combination is active and well tolerated in patients with advanced stage previously untreated INFL. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

46. Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

Author

Pellegrini, Cinzia, Broccoli, Alessandro, Casadei, Beatrice, Chiappella, Annalisa, Corradini, Paolo, Derenzini, Enrico, Dodero, Anna, Farina, Lucia, Gandolfi, Letizia, Ladetto, Marco, Monaco, Federico, Orsucci, Lorella, Quirini, Federica, Salvi, Flavia, Spina, Francesco, Stefoni, Vittorio, Tonialini, Lorenzo, Vitolo, Umberto, Argnani, Lisa, and Zinzani, Pier Luigi

Published
2015
Full Text
View/download PDF

47. Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Author

Santoro, Armando, Mazza, Rita, Pulsoni, Alessandro, Re, Alessandro, Bonfichi, Maurizio, Zilioli, Vittorio Ruggero, Salvi, Flavia, Anastasia, Antonella, Luminari, Stefano, Gotti, Manuel, Peli, Annalisa, Liberati, Anna Marina, Di Renzo, Nicola, Castagna, Luca, Giordano, Laura, and Carlo-Stella, Carmelo

Published
2015
Full Text
View/download PDF

48. Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial

Author

Oliva, Esther Natalie, Santini, Valeria, Alati, Caterina, Poloni, Antonella, Molteni, Alfredo, Niscola, Pasquale, Sanpaolo, Grazia, Salvi, Flavia, Palumbo, Giuseppe A., Balleari, Enrico, Impera, Stefana, Cortelezzi, Agostino, Liberati, Anna Marina, Avanzini, Paolo, Di Bartolomeo, Paolo, Rose, Christian, Beyne-Rauzy, Odile, Buccisano, Francesco, Bocchia, Monica, Morabito, Fortunato, Stamatoullas, Aspasia, Ronco, Francesca, Zini, Gina, D'Errigo, Maria Grazia, Ranieri, Natale, Cufari, Patrizia, Santacaterina, Irene, Fenaux, Pierre, and Latagliata, Roberto

Published
2015
Full Text
View/download PDF

49. Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study

Author

Voso, Maria Teresa, Leone, Giuseppe, Piciocchi, Alfonso, Fianchi, Luana, Di Bartolomeo, Paolo, Candoni, Anna, Criscuolo, Marianna, Masciulli, Arianna, Cerqui, Elisa, Molteni, Alfredo, Finelli, Carlo, Parma, Matteo, Rivellini, Flavia, Cascavilla, Nicola, Spina, Francesco, Cortelezzi, Agostino, Salvi, Flavia, Montanari, Mauro, Alessandrino, Emilio Paolo, Rambaldi, Alessandro, and Sica, Simona

Published
2015
Full Text
View/download PDF

50. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization.

Author

Rossi, Giuseppe, Skert, Cristina, Morello, Enrico, Almici, Camillo, Arcaini, Luca, Basilico, Claudia, Cavalli, Lara, Botto, Barbara, Castelli, Andrea, Pica, Gianmatteo, Ripamonti, Francesco, Salvi, Flavia, Carella, Angelo M., Gaidano, Gianluca, Levis, Alessandro, Nosari, Annamaria, Russo, Domenico, and Vitolo, Umberto

Abstract

Autologous stem cell transplantation (ASCT) is a potentially curative treatment of lymphoma, but peripheral blood stem cell (PBSC) mobilization fails in some patients. PBSC mobilizing agents have recently been proved to improve the PBSC yield after a prior mobilization failure. Predictive parameters of mobilization failure allowing for a preemptive, more cost-effective use of such agents during the first mobilization attempt are still poorly defined, particularly during mobilization with chemotherapy + granulocyte colony-stimulating factor (G-CSF). We performed a retrospective analysis of a series of lymphoma patients who were candidates for ASCT, to identify factors influencing PBSC mobilization outcome. Premobilization parameters-age, histology, disease status, mobilizing protocol, and previous treatments-as well as white blood cell (WBC) and PBSC kinetics, markers potentially able to predict failure during the ongoing mobilization attempt, were analyzed in 415 consecutive mobilization procedures in 388 patients. We used chemotherapy + G-CSF in 411 (99%) of mobilization attempts and PBSC collection failed (<2 × 10(6) CD34+ PBSC/kg) in 13%. Multivariable analysis showed that only a low CD34+ PBSC count and CD34+ PBSC/WBC ratio, together with the use of nonplatinum-containing chemotherapy, independently predicted mobilization failure. Using these three parameters, we established a scoring system to predict risk of failure during mobilization ranging from 2 to 90%, thus allowing a selective use of a preemptive mobilization policy. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results